AOTMiT: Transparency Council on lipid disorders and urothelial cancer, among others

The agenda includes:

1. Preparation of a position paper on the evaluation of the drug Leqvio (inclisiranum) under the drug program B.101. "Treatment of patients with lipid disorders (ICD-10: E78.01, I21, I22, I25)".
2. Preparation of a position paper on the evaluation of the drug Repatha (evolocumabum) under the drug program B.101. "Treatment of patients with lipid disorders (ICD-10: E78.01, I21, I22, I25)".
3. Preparation of a position paper on the evaluation of the drug Praluent (alirocumabum) under the drug program B.101. "Treatment of patients with lipid disorders (ICD-10: E78.01, I21, I22, I25)".
4. Preparation of an opinion on the unification of the provisions of the drug program B.101. "Treatment of patients with lipid disorders (ICD-10: E78.01, I21, I22, I25)".
5. Preparation of a position paper on the evaluation of the drug Keytruda (pembrolizumab) in combination with enfortumab vedotin under the drug program B.141.FM. "Treatment of patients with urothelial carcinoma (ICD-10: C61, C65, C66, C67, C68)".
6. Preparation of a position paper on the evaluation of the drug Padcev (enfortumabum vedotini) in combination with pembrolizumab under the drug program B.141.FM. "Treatment of patients with urothelial carcinoma (ICD-10: C61, C65, C66, C67, C68)".
7. Preparation of an opinion on the draft health policy program of the local government unit "Municipal Program for Promotion of Mental Health of Boguchwała Municipality residents for 2025-2026".
8. Preparation of an opinion on the draft health policy program of the local government unit "Health policy program for laserobaria treatment of chronic wounds for the residents of Wągrowiec County for 2025-2026".

Source: AOTMIT